Transplantation of purified hematopoietic stem cells: Requirements for overcoming the barriers of allogeneic engraftment

Biology of Blood and Marrow Transplantation

Volumn 2, Issue 1, 1996, Pages 3-14

  Shizuru, Judith A ^a   Jerabek, Libuse ^a   Edwards, Cariel T ^a   Weissman, Irving L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic stem cell transplantation; Mice; Natural killer cell associated antigens

Indexed keywords

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL SEPARATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL SEPARATION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030072986     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PF, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation. N Engl J Med 292:832, 1975.
2. Ramsay NKC, Kersey JH, Robison LL, McGlave PB, Woods WG, Krivit W, Kim TH, Goldman AL, Nesbit ME: A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306:392, 1982.
3. Storb R, Deeg J, Fisher L, Appelbaum F, Buckner CD, Bensinger W, Clift R, Doney K, Irle C, McGuffin R, Martin P, Sanders J, Schoch G, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Cyclosporine vs. methotrexate for graft-vs.-host disease prevention in patient given marrow grafts for leukemia: Long term follow-up of three controlled trials. Blood 71:293, 1988.
4. Storb R, Deeg J, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Loughran T, Martin P, Singer J, Sanders J, Stewart P, Sullivan K, Witherspaon R, Thomas ED: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729, 1989.
5. Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, Goldstein G: Use of anti-T-cell monoclonal antibody OKT3 to prevent graft-versus-host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet 1:700, 1982.
6. Martin PJ, Hansen JA, Buckner CD, Sanders EJ, Deeg J, Stewart P, Appelbamn FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Fluornoy N, Storb R, Thomas ED: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985.
7. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, Terasaki P, Billing R, Feig S: Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft-versus-host disease. Ann Int Med 105:20, 1986.
8. Ash RC, Casper JT, Chitambaar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA, Gottschall JL, Oldham K, Anderson MD, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donor. N Engl J Med 322:485, 1990.
9. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK: Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 83:3090, 1994.
10. Ferrara JLM, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667, 1991.
11. Vallera DA, Soderling CB, Carlson GJ, Kersey JH: Bone marrow transplantation across major histocompatibility barriers in mice: Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement of antibody alone. Transplantation 31:218, 1981.
12. Cudkowicz G, Bennett M: Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exp Med 134:83, 1971.
13. Bennett M: Biology and genetics of hybrid resistance. Adv Immunol 41:333, 1987.
14. Yu YYL, Kumar V, Bennett M: Murine natural killer cells and marrow graft rejection. Annu Rev Immunol 19:189, 1992.
15. v anemic mice: Effect of disparity at the Ea-2 locus. Immunogenetics 2:219, 1975.
16. 1 hybrid resistance: Long-term systemic effects sensitive to irradiation and age. Immunogenetics 13:177, 1981.
17. Gorer PA, Lyman S, Snell GD: Studies on the genetic and antigenic basis of tumour transplantation. Linkage between a histocompatibility gene and "fused" in mice. Proc R Soc Lond G 135:499, 1948.
18. Gotze D (ed): The Major Histocompatibility System in Man and Animals. Berlin: Springer-Verlag, 1977.
19. Yokoyama WM, Seaman WE: The Ly-49 and NKR-P1 gene families encoding lectin-receptors on natural killer cells: The NK gene complex. Annu Rev Immunol 11:613, 1993.
20. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G: Evidence for a similar common mechanism for natural killer cell activity and resistance to hematopoietic grafts. Eur J Immunol 7:655, 1977.
21. Cudkowicz G, Hochman PS: Do natural killer cells engage in regulated reaction against self to insure homeostasis? Immunol Rev 44:13, 1979.
22. Murphy WJ, Kumar V, Bennett M: Acute rejection of murine bone marrow allografts by natural killer cells. Differences in kinetics and target antigens recognized. J Exp Med 166:1499, 1987.
23. Murphy WJ, Reynolds CW, Tiberghien P, Long DL: Natural killer cells and bone marrow transplantation. J Natl Cancer Inst 85:1475, 1993.
24. von Melcher H, Bartlett PF: Mechanism of early allogeneic graft rejection. Immunol Rev 71:31, 1983.
25. Dennert G, Anderson CG, Warner J: T killer cells play a role in allogeneic bone marrow graft rejection but not hybrid resistance. J Immunol 135:3729, 1985.
26. Cobbold SP, Martin G, Qin S, Waldmann H: Monoclonal antibodies to promote marrow engraftment and tissue tolerance. Nature 323:164, 1986.
27. lo hematopoietic stem cell. Cell 44:653, 1986.
28. Lepault F, Weissman IL: An in vivo assay for thymus-homing bone marrow cells. Nature 293:151, 1981.
29. Ezine SV, Weissman IL, Rouse RV: Bone marrow cells give rise to distinct cell clones within the thymus. Nature 309:629, 1984.
30. Spangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoietic stem cells. Science 241:58, 1988.
31. + cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J Exp Med 175:175, 1992.
32. Baum CM, Weissman IL, Tsukamoto AS, Buckle A-M, Peault B: Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89:2804, 1992.
33. + hematopoietic stem cells. Blood 83:3758, 1994.
34. Morrison SJ, Weissman IL: The long term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotypes. Immunity 1:661, 1994.
35. 50 and death rate studies. Radiat Res 5:300, 1956.
36. Kasai M, Yoneda T, Habu S, Maruyama Y, Okumura K, Tokunaga T: In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature 291:334, 1981.
37. + cells in the resistance of transplants of bone marrow or other tissues. In: RB Herberman (ed) NK Cells and Other Natural Effector Cells. New York: Academic Press, 1982.
38. Lotzová E, Savary CA, Pollack SB: Prevention of rejection of allogeneic bone marrow transplants by NK1.1 antiserum. Transplantation 35:490, 1983.
39. b. Eur J Immunol 21:282, 1991.
40. Tiberghien P, Longo DL, Wine JW, Alvord G, Reynolds CW: Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: Evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 76:1419, 1990.
41. Castaño L, Eisenbarth G: Type I diabetes. A chronic autoimmune disease of human, mouse and rat. Annu Rev Immunol 8:647, 1990.
42. Ikehara S, Ohtsuki H, Good RA, Asamoto H, Nakamura T, Sekita K, Muso E, Tochino Y, Ida T, Kuzuya H, Imura H, Hamashima Y: Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 82:7743, 1985.
43. LaFace DM, Peck AB: Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes 38:894, 1989.
44. Todd JA, Bell JI, McDevitt HO: HLA DQβ gene contributes to susceptibility and resistance to insulin dependent diabetes. Nature 329:599, 1987.
45. Strober S, Weissman IL: Immunosuppressive and tolerogenic effects of whole body, total lymphoid and regional irradiation. In: JR Salaman (ed) The Current Status of Modern Therapy, Volume 7. Lancaster, England: MTP Press, 9, 1981.
46. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG: Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science 240: 659, 1988.
47. Simonsen M: Graft versus host reactions. Their natural history and applicability as tools of research. In: P Kallos, BH Waksman (eds) Progress in Allergy, Volume VI. Basel: Karger, 349, 1962.
48. Martin PJ: Determination of engraftment after allogeneic marrow transplantation. Blood 79:1647, 1992.
49. Uharek L, Gassman W, Glass B, Steinmann J, Loeffler H, Mueller-Rucholtz W: Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 79:1612, 1992.
50. Palathumpat VS, Dejbakhsh-Jones S, Holm B, Strober S: Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 149:808, 1992.
51. Dejbakhsh-Jones S, Jerabek L, Weissman IL, Strober S: Extrathymic maturation of α/β T cells from hemopoietic stem cells. J Immunol, in press.
52. Murphy WJ, Kumar V, Cope JC, Bennett M: An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells. J Immunol 144:3305, 1990.
53. Lapidot T, Lubin I, Terenzi A, Faktorowich Y, Erlich P, Reisner Y: Enhancement of bone marrow allografts from nude mice into recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci USA 87:4595, 1990.
54. Martin, P: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 178:703, 1993.
55. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST: Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 84:2436, 1994.
56. Murphy WJ, Bennett M, Kumar V, Longo D: Donor type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 148:2953, 1992.
57. Murphy WJ, Keller JR, Harrison CL, Young HA, Longo DL: Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 80:670, 1992.
58. Sykes M, Sheard M, Sachs DH: Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol 141:2282, 1988.
59. Sykes M, Chester CH, Sundt TM, Romick ML, Hoyles KA, Sachs DH: Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients. J Immunol 143:3503, 1989.
60. Lagasse E, Weissman IL: Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med 177:104, 1994.
61. Shultz LD, Schweiter PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH: Multiple defects in innate and adaptive immunologic function in KOD/LtSz-scid mice. J Immunol 154:180, 1995.
62. Serreze DV, Leiter EH: Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol 140:3801, 1988.